Thermo Fisher Scientific (NYSE:TMO) Price Target Increased to $686.00 by Analysts at TD Cowen

Thermo Fisher Scientific (NYSE:TMO) had its price objective boosted by TD Cowen from $656.00 to $686.00 in a report published on Tuesday morning.

Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. increased their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Stifel Nicolaus upped their price objective on Thermo Fisher Scientific from $615.00 to $680.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Raymond James increased their target price on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $767.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, September 20th. Finally, Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $656.00.

Thermo Fisher Scientific Trading Down 1.5 %

NYSE:TMO opened at $586.25 on Tuesday. The firm has a 50 day moving average of $607.55 and a 200 day moving average of $584.45. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a 52 week low of $415.60 and a 52 week high of $627.88. The stock has a market capitalization of $223.95 billion, a price-to-earnings ratio of 36.37, a PEG ratio of 3.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. The company had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same period in the prior year, the company posted $5.15 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific will post 21.72 earnings per share for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 860 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $611.03, for a total transaction of $525,485.80. Following the sale, the chief accounting officer now owns 1,814 shares in the company, valued at $1,108,408.42. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 860 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the sale, the chief accounting officer now directly owns 1,814 shares of the company’s stock, valued at approximately $1,108,408.42. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.95. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,084 shares of company stock valued at $14,094,292. Insiders own 0.34% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

A number of institutional investors have recently made changes to their positions in the stock. Greystone Financial Group LLC lifted its position in Thermo Fisher Scientific by 3.2% in the third quarter. Greystone Financial Group LLC now owns 3,227 shares of the medical research company’s stock worth $1,996,000 after purchasing an additional 100 shares during the period. Great Lakes Retirement Inc. lifted its holdings in shares of Thermo Fisher Scientific by 2.0% in the third quarter. Great Lakes Retirement Inc. now owns 4,794 shares of the medical research company’s stock valued at $2,966,000 after buying an additional 96 shares during the period. Tanager Wealth Management LLP boosted its stake in Thermo Fisher Scientific by 3.8% during the third quarter. Tanager Wealth Management LLP now owns 1,008 shares of the medical research company’s stock valued at $624,000 after buying an additional 37 shares in the last quarter. International Assets Investment Management LLC raised its position in Thermo Fisher Scientific by 76,051.4% in the third quarter. International Assets Investment Management LLC now owns 1,416,416 shares of the medical research company’s stock worth $876,152,000 after acquiring an additional 1,414,556 shares in the last quarter. Finally, Monte Financial Group LLC lifted its holdings in Thermo Fisher Scientific by 2.7% in the 3rd quarter. Monte Financial Group LLC now owns 2,213 shares of the medical research company’s stock valued at $1,369,000 after acquiring an additional 58 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.